Interferon and other proinflamatory cytokine responses in vitro following infection with wild-type and cold-adapted reassortant influenza viruses

Rekstin, Andrey; Kiseleva, Irina; Klimov, Alexander; Katz, Jacqueline M.; Rudenko, Larisa

doi:10.1016/j.vaccine.2006.05.091

Cited by 8 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Viruses were introduced with a multiplicity of infection (MOI) of 0.1 - 0.01/1 ml. To determine the multiplicity of infection, viruses were titrated in MDCK cells with determination of infectious titers by conventional methods as described elsewhere [7] . The supernatants were collected 24 h after infection.…”

Section: Methodsmentioning

confidence: 99%

Assessment of trivalent live influenza vaccines in MDCK cell line

2021

Self Cite

View full text Add to dashboard Cite

We applied a one-step reverse transcriptase real-time PCR (rRT-PCR) analysis using TaqMan technique to evaluate the infectious titers of vaccine strains containing in trivalent live influenza vaccines (LAIVs). The cold-adapted reassortant influenza viruses A/H1N1 pdm09, A/H3N2, B/Yamagata and B/Victoria, included in the composition of the LAIV in 2015-2016, 2017-2018 and 2018-2019 flu season were studied for reproductive activity in MDCK cells as part of a mono-vaccine and tri-vaccine. For this we have developed a set of specific primers and probes. Method validation was performed using ELISA-test after mouse monoclonal antibodies to hemagglutinin (HA) staining of MDCK monolayer. Influenza B viruses B/Yamagata and B/Victoria were studied in MDCK cells in mono-infection and coinfection with different multiplicity of infection (MOI) using quantitative rRT-PCR. RT-PCR analysis was adjusted to assess the growth characteristics of cold-adapted reassortant influenza viruses in MDCK cell line. The greatest suppression in the composition of the tri-vaccine was exposed to the H1N1 pdm09 LAIV component. Influenza B viruses are least suppressed in trivalent LAIV. Influenza viruses B/Yamagata and B/Victoria reproduced as part of a mixed preparation not lower, if not better than as a mono-preparation at an MOI of 0.1. At an MOI of 0.01, the reproduction of both B/Yamagata and B/Victoria in the mixture was reduced compared to mono-vaccine. The interference of trivalent LAIV vaccine viruses in MDCK cells was minimal at low dilutions. This indicates that it is undesirable to reduce the titers of vaccine viruses, including at the stages of transportation and storage of LAIV

show abstract

Section: Methodsmentioning

confidence: 99%

Assessment of trivalent live influenza vaccines in MDCK cell line

2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previously it was shown that in the early stages of infection the macrophages produce significant amounts of antiviral cytokines IFN 1-alpha (more than epithelial cells) [17] and chemokines involved in the migration process of leukocytes from circulation to the focus of inflammation. Our early investigations demonstrated that human macrophages after treatment with both live and inactivated influenza A viruses produced type 1 interferon at 24 hours after inoculation [18]. Thus, viral replication was not a necessary condition in this system, although macrophages treated with inactivated virus produced less interferon, compared to macrophages treated with live virus.…”

Section: Discussionmentioning

confidence: 91%

Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

Desheva

Leontieva

Kramskaya

et al. 2019

Heliyon

View full text Add to dashboard Cite

We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs.Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.

show abstract

“…If epithelial cells are a natural barrier that protects the body from pathogens, then macrophages form a second line of defense against infections and contribute to the secretion of immunostimulatory cytokines, chemokines and interferons during influenza infection. Compared to epithelial cells, macrophages produce more amounts of IFN-α and chemokines, which play a role in the relocation and recruitment of leukocytes to the site of inflammation from the circulation [ 35 ]. In the culture of human macrophages, THP-1 both PSPF and LAIV+PSPF caused a noticeable increase in the cytokines production.…”

Section: Discussionmentioning

confidence: 99%

Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model

et al. 2022

View full text Add to dashboard Cite

Severe influenza complications are often caused by Streptococcus pneumoniae infection, which presents the most common cause of community-acquired pneumonia. We evaluated in a mouse model an associated virus-bacterial vaccine based on seasonal live influenza vaccines (LAIV) and S. pneumoniae chimeric protein comprising flagellin (PSPF). Intranasal immunization of mice with a complex of trivalent LAIV and PSPF caused an increased release of early cytokines in the lungs of mice. The immunogenicity of LAIV and PSPF in the associated vaccine composition was sometimes decreased compared to each vaccine preparation alone. Nevertheless, only vaccination of mice with LAIV+PSPF significantly reduced lethality and the bacterial load in the lungs in a model of post-influenza bacterial pneumonia. The study of the interactions of influenza viruses with bacterial peptides is important during the development of associated virus-bacterial vaccines intended for the prevention of severe post-influenza bacterial complications.

show abstract

Interferon and other proinflamatory cytokine responses in vitro following infection with wild-type and cold-adapted reassortant influenza viruses

Cited by 8 publications

References 5 publications

Assessment of trivalent live influenza vaccines in MDCK cell line

Assessment of trivalent live influenza vaccines in MDCK cell line

Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model

Contact Info

Product

Resources

About